Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.
In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.
Study Type
OBSERVATIONAL
Enrollment
161
500 mg Quevir® (Quercetin Phytosome®) tablet
Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
Dr. Buccomino Medical Clinic
Milan, Italy
Change in plasma uric acid level
Supplement effect on plasma uric acid level
Time frame: 90 days
Change in plasma cholesterol level
Supplement effect on plasma cholesterol level
Time frame: 90 days
Change in plasma triglycerides level
Supplement effect on plasma triglycerides level
Time frame: 90 days
Change in plasma glucose level
Supplement effect on plasma glucose level
Time frame: 90 days
Change in plasma insulin level
Supplement effect on plasma insulin level
Time frame: 90 days
Change in plasma creatine phosphokinase level
Supplement effect on plasma creatine phosphokinase level
Time frame: 90 days
Change in alanine transaminase level
Supplement effect on liver function
Time frame: 90 days
Change in aspartate aminotransferase level
Supplement effect on liver function
Time frame: 90 days
Change in alkaline phosphatase level
Supplement effect on liver function
Time frame: 90 days
Change in gamma-glutamyl transferase level
Supplement effect on liver function
Time frame: 90 days
Change in bilirubin level
Supplement effect on liver function
Time frame: 90 days
Incidence of side effects
Number of patients reporting side effects
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.